Preparative Lymphodepleting Chemotherapy - Biology & Toxicity
Autologous and allogeneic CAR-T cell regimens incorporate lymphodepleting chemotherapy which supports the expansion of the therapy. Chemotherapy increases the risk of opportunistic infections and confounds the diagnosis of CRS/ICANs contributing to the requirement for patients to be in proximity of tertiary care centers.
Lymphodepleting Chemotherapy
Direct and Indirect Effects Have Heightened Risk in Autoimmune Patients
Chemotherapy-free CAR-T Therapy
At EXUMA Biotech, solutions that are not only safe and effective, but also accessible, are a part of our core values. We have applied science and innovation towards improving access and safety to potentially allow for cell therapy administration in broader settings of care in the future. Because of the CD3 LV and FITNESS DRIVER technologies, both rPOC SC and GCAR have eliminated the use of lymphodepleting chemotherapy and the associated risks.
Developing Autologous Cell Therapies, Free From Chemotherapy
Patients obtain cell therapy from their existing care team
